Key points from article :
Chroma Medicine snagged $135 million in Series B financing amidst a challenging economic landscape.
Chroma’s approach to genetic medicines avoids the pitfalls of traditional CRISPR gene editing.
“Had this technology been initially developed ... epigenetic editing would be the modality of choice for gene editing,” said Catherine Stehman-Breen, CEO.
She credited the investors’ deep interest in the company to its “superior approach for gene regulation” and rapid progress in unlocking the technology’s potential.
Google’s investment arm made a bet on Aera Therapeutics, which emerged from stealth mode with a combined Series A and B financing.
The $193 million will fuel Aera’s efforts to solve one of genetic medicine’s biggest hurdles – delivery.
ARCH Venture Partners also went in on both Chroma and Aera.
